Ironwood Pharmaceuticals (IRWD) Jefferies London Healthcare Conference 2024 summary

Updated financial guidance and business outlook

• 2024 net trade sales are guided at $900–$950 million, with adjusted EBITDA expected above $75 million.

• Medicaid utilization increased in 2023 and is now reflected in 2024 guidance, with payer mix and gross-to-net expected to remain stable through year-end.

• Linzess demand continues double-digit growth in 2024, but government pricing, especially Medicare Part D redesign, is a headwind; more clarity on 2025 will be provided next year.

• Commercial margins show seasonal improvement, with Q4 typically the most profitable due to deductible dynamics.

• Free cash flow remains positive, used to pay down debt from the VectivBio acquisition; credit facility extended to December 2028 with added capacity.

Strategic brand management and payer dynamics

• Profitability levers include optimizing DTC, field, and marketing spend, with ongoing collaboration with AbbVie.

• Commercial spend can be adjusted, but some changes have multi-quarter lead times due to advance media buys.

• Payer contracting discussions are positive and align with expectations; access negotiations intensify as the product matures.

• IRA pricing impact is uncertain; preparations are underway for all outcomes.

Linzess market and competitive landscape

• Linzess maintains leadership in IBS-C, benefiting from a large, underserved patient population and reduced prescription barriers.

• Prescription therapy market for IBS-C is expanding, with Linzess capturing a disproportionate share.